Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push
I'm PortAI, I can summarize articles.
Eli Lilly announced plans to build a $3.5 billion pharmaceutical manufacturing plant in Pennsylvania, aimed at producing injectable weight-loss drugs, including retatrutide. This facility, expected to create at least 850 jobs, is part of Lilly's strategy to expand U.S. production amid potential import tariffs. Construction is set to begin in 2026, with operations starting in 2031. This investment marks the largest by a life sciences company in Pennsylvania's history, reflecting a broader trend among pharmaceutical firms to enhance domestic manufacturing capabilities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments